1. Home
  2. HKPD vs CASI Comparison

HKPD vs CASI Comparison

Compare HKPD & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HKPD
  • CASI
  • Stock Information
  • Founded
  • HKPD 2016
  • CASI 1991
  • Country
  • HKPD Hong Kong
  • CASI China
  • Employees
  • HKPD N/A
  • CASI N/A
  • Industry
  • HKPD Other Pharmaceuticals
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • HKPD Health Care
  • CASI Health Care
  • Exchange
  • HKPD Nasdaq
  • CASI Nasdaq
  • Market Cap
  • HKPD 20.9M
  • CASI 20.5M
  • IPO Year
  • HKPD 2025
  • CASI 1996
  • Fundamental
  • Price
  • HKPD $1.07
  • CASI $2.38
  • Analyst Decision
  • HKPD
  • CASI Strong Buy
  • Analyst Count
  • HKPD 0
  • CASI 1
  • Target Price
  • HKPD N/A
  • CASI $4.00
  • AVG Volume (30 Days)
  • HKPD 70.4K
  • CASI 3.7M
  • Earning Date
  • HKPD 01-01-0001
  • CASI 08-26-2025
  • Dividend Yield
  • HKPD N/A
  • CASI N/A
  • EPS Growth
  • HKPD N/A
  • CASI N/A
  • EPS
  • HKPD 0.21
  • CASI N/A
  • Revenue
  • HKPD $20,770,344.00
  • CASI $31,368,000.00
  • Revenue This Year
  • HKPD N/A
  • CASI N/A
  • Revenue Next Year
  • HKPD N/A
  • CASI N/A
  • P/E Ratio
  • HKPD $4.97
  • CASI N/A
  • Revenue Growth
  • HKPD 32.91
  • CASI 8.39
  • 52 Week Low
  • HKPD $0.81
  • CASI $1.09
  • 52 Week High
  • HKPD $3.79
  • CASI $7.67
  • Technical
  • Relative Strength Index (RSI)
  • HKPD N/A
  • CASI 70.81
  • Support Level
  • HKPD N/A
  • CASI $1.46
  • Resistance Level
  • HKPD N/A
  • CASI $2.03
  • Average True Range (ATR)
  • HKPD 0.00
  • CASI 0.35
  • MACD
  • HKPD 0.00
  • CASI 0.07
  • Stochastic Oscillator
  • HKPD 0.00
  • CASI 61.75

About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: